drugset / Trial / NCT01043458

Pharmacokinetic Study of ABT-126 in Stable Subjects With Schizophrenia

NCT01043458

Phase 1 Completed 16 enrolled Abbott
RandomizedParallel-groupDouble-blindTreatment

Summary

A study to investigate the process by which ABT-126 is absorbed, distributed, metabolized and eliminated by the body of stable schizophrenic volunteers receiving treatment with an atypical antipsychotic.

Timeline

Start
2009-11
Primary completion
2010-01
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject ABT-126 Small molecule

Indications